Nektar Therapeutics is moving forward with its lead immunology candidate, rezpegaldesleukin, after long-term data from a mid-stage trial provided enough clarity to warrant a Phase 3 program. The drug, an IL-2 conjugate designed to stimulate regulatory T cells, is being positioned as a potential treatment for alopecia areata, an autoimmune condition that causes patchy or total hair loss.
The new data comes from an extension phase of a Phase 2b study that initially failed to meet its primary endpoint in a broader population. However, the extended results suggest that patients who remained on the therapy experienced a durable response, with some seeing continued improvement in hair regrowth over 52 weeks. For a biotech company that has faced several high-profile clinical setbacks in recent years, these results represent a necessary stabilization of its pipeline.
Wall Street analysts viewed the data as meeting "base case" expectations—sufficiently positive to justify the cost of late-stage trials but not yet a definitive signal of market dominance. Nektar now faces the challenge of proving that rezpegaldesleukin can compete in an increasingly crowded immunology landscape, where Janus kinase (JAK) inhibitors have already established a foothold. The company’s pivot toward regulatory T-cell modulation reflects a broader industry shift toward more targeted, potentially safer alternatives to systemic immunosuppression.
With reporting from Endpoints News.
Source · Endpoints News
